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Abstract
Background:  The identification of antigens on human DC has been a very difficult and elusive
task because of the lack of appropriate reagents. Therefore, we evaluated by flow cytometry a panel
of mAb that recognize antigens on human DC, aiming to determine the kinetics of DC antigen
expression at 7, 14, 21 and 28 days in (i) Dermal DC like cells (Mo-DC) and (ii) Langerhans cell like
DC (Mo-LC). In addition we aimed to identify markers for DC subpopulations.
Results:  It was found at day 7, that mAb BG6, HP-F1, BU10, RFD-1, CMRF-44 recognized <20%
of Mo-DC. In contrast, 7H5, ZM3.8, CDlb/c, 55K-2, MMR1.16, MMR190.BB3 and L25 reacted with
>50% of Mo-DC. Moreover, 7H5, ZM3.8, CMRF-56, CDlb/c, 55K-2, MMR1.16, MMR190.BB3 and
L25 showed increased MFI reactivity against Mo-DC. mAb BG6, BU10 and CMRF-44 recognized
<20% Mo-LC while RFD-1 reacted with 21% of Mo-LC. In contrast, HP-F1 showed 87% of Mo-LC
positive. Also, 7H5, ZM3.8, RFD-7, MR15-2, CDlb/c, 55K-2, MMR1.16, MMR190.BB3 and L25
reacted with >50% of Mo-LC. The increase in % of positive cells was paralleled by MFI increases.
At day 14, fourteen mAb recognized >50% of the Mo-DC, while five recognized 20-50% of Mo-DC.
BG6 reacted with 7% of the Mo-DC. Nineteen mAb recognized >48% of Mo-LC while BG6 had
negative reactivity.
At day 21 and 28, all mAb reacted with >20% of Mo-DC and yielded a significant MFI with Mo-DC.
Also nineteen mAb yielded significant MFI with Mo-LC while RFD-7 did not.
Conclusions:  The immunophenotyping assays demonstrated differences between the two DC
populations as well as variations in the reactivity of the mAb at diverse time points, suggesting the
existence of subpopulations within the Mo-DC and Mo-LC.
Background
Dendritic cells (DC) are a complex group of mainly bone
marrow derived cells that play an important role in the
afferent branch of the immune response [1]. However,
DC represents only a minute subpopulation of the pe-
ripheral blood mononuclear cells (PBMC), as well as of
bulk cellular populations of the lung, intestine, geni-
tourinary tissue, and lymphoid tissue. DC also has been
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found in the epidermis, dermis and mucous membranes
and constituting about 2% of the total cellular population
of the human epidermis [2,3]. The Langerhans cells (LC)
are a skin derived-DC, that have the capability to travel
to the regional lymphoid organs after take up of antigen
and undergo there an activation/maturation step. There-
after, LC interacts and activates T cells. Because of such
significant capability to take up soluble antigens, process
and present them to responder cells in the lymphoid tis-
sues in the context of the restricted MHC pathway, LC
have been considered one of the most important ele-
ments in the afferent arm of the immune response [1–4].
Recent, successful efforts to generate DC from PBMC de-
rived monocytes or from CD34 blood precursors by uti-
lizing GM-CSF and IL-4, as well as GM-CSF and/or TNF,
has enabled us to obtain PBMC derived DC (Mo-DC))
[5–8]. In addition, an approach has been developed to
generate LC from isolated monocytes (Mo-LC) [9].
Despite the successful efforts in the generation of DC
from blood precursors, the characterization of surface
markers on human DC has been a very difficult and elu-
sive task because the lack of appropriate reagents with
high specificity for DC identification [4]. However, some
molecules whose genes recently have been cloned and se-
quenced (e.g. CD83, DEC-205) have been found strongly
associated with DC [5,6]. In addition, a panel of mono-
clonal antibodies (e.g. CMRF-44) that recognize mole-
cules on DC has been raised [7]. There is a growing need
for cluster and establishment of a common and compre-
hensive nomenclature for such DC associated molecules,
as well as to clarify and define the lineage(s) of DC and
the existence of DC subsets. These developments have
prompted the set up of diverse approaches that evaluated
the reactivity of a group of mAb against populations of
DC [10–29]. Therefore and within the scope of this
study, we set up a flow cytometry approach and evaluat-
ed a panel of 20 mAb against two populations of DC aim-
ing to determine the kinetics of expression of antigens on
DC at diverse intervals of time and the likelihood to iden-
tify markers for DC subsets [12–29].
Results and Discussion
Flow cytometric assessments of monoclonal antibodies
(mAb) reactivity against dendritic cells (DC) was under-
taken by measurement of the % of reactivity (Figure
1,2,3,4) and mean fluorescent intensity (MFI) of two
populations of DC at 7, 14, 21 and 28 days (Table 1). At
day 7 (Figure 1), the flow cytometry evaluation showed
that, antibodies 70011 (BG6), 70194 (HP-F1 (CD85i)),
70293 (BU10), 70511 (RFD-1) and 70375 (CMRF-44)
recognized less than 20 % of Mo-DC. In contrast, 70345
(7H5 (CD85a)), 70358 (ZM3.8 (CD85j)), 70807 (CDlb/
c), 70806 (55K-2 fascin), 70776 (MMR1.16 (CD206)),
70767 (MMR190.BB3 (CD206)) and 70772 (L25) reacted
with more than 50% of Mo-DC. Moreover, 70345 (7H5
(CD85a)), 70358 (ZM3.8 (CD85j)), 70376 (CMRF-56),
70807 (CDlb/c), 70806 (55K-2 fascin), 70776 (MMR1.16
(CD206)), 70767 (MMR190.BB3 (CD206)) and 70772
(L25) also showed increase MFI reactivity against Mo-
DC (Table 1).
The mAb 70011 (BG6), 70293 (BU10) and 70375 (CM-
RF-44) recognized less than 20% Mo-LC while 70511 re-
acted with only 21% of the cells. In contrast, 70194 (HP-
F1 (CD85i)) showed that 87% of Mo-LCs were positive.
Also, 70345 (7H5 (CD85a)), 70358 (ZM3.8 (CD85j)),
70512 (RFD-7), 70802 (MR15-2 (CD205)), 70807
(CDlb/c), 70806 (55K-2 fascin), 70776 (MMR1.16
(CD206)), 70767 (MMR190.BB3 (CD206)), 70772 (L25)
reacted with more than 50% of Mo-LC. The increase in %
of positive cells was also paralleled by MFI increases (Ta-
ble 1).
At day 14 (Figure 2), 14 mAb recognized more than 50%
of the Mo-DC, while 70427 (DCGM-4 (CD207)), 70451
(TPD153), 70511 (RFD-1), 70512 (RFD-7) and 70375
(CMRF-44) recognized between 20 and 50% of Mo-DC.
70011 (BG6) reacted with 7% of the Mo-DC. The reactiv-
ity of 70011 (BG6) against Mo-LC was indistinguishable
from the background while the other nineteen mAb rec-
ognized more than 48% of Mo-LC. At day 21 and 28, all
the mAb reacted with more than 20% of Mo-DC (Figure
3 and 4). Also, the mAb yielded a significant MFI with
Mo-DC (Table 1). In addition, nineteen mAb yielded sig-
nificant MFI with Mo-LC whilst only 70512 (RFD-7) did
not. (Table 1) At day 21 (Figure 3), seventeen mAb react-
ed with more than 50% of the Mo-DC, only 70346 (42D1
Figure 1
Percentage of positive cells detected by mAb against Mo-DC
and LC-DC after 7 days of cultureBMC Immunology (2001) 2:6 http://www.biomedcentral.com/1471-2172/2/6
(CD85f)), 70511 (RFD-1) and 70512 (RFD-7) were below
50%. In contrast, only seven mAb reacted with more
than 50% Mo-LC but only 70512 (RFD-7) reacted with
less than 20% Mo-LC. At day 28 (Figure 4), sixteen mAb
reacted with more than 50% Mo-DC. The mAb 70346
(42D1 (CD85f)), 70511 (RFD-1), 70512 (RFD-7) and
70808 (DEC-205 (CD205)) were below 50% while 70375
(CMRF-44) reacted with less than 20% of Mo-LC. Seven-
teen mAb reacted with more than 50% of Mo-LC.
The simultaneous evaluation on Mo-DC and Mo-LC of
FSC (flow cytometric assessment of size) and mAb reac-
tivity at four time points demonstrated the presence of
significant variability within the Mo-DC and Mo-LC pop-
ulations (Figure 5). At day seven, there was several mAb
that showed strong reactivity and can be grouped togeth-
er (Figure 5 panel C mAb-MMR.190.BB3 and panel E
mAb-L25). In addition there was another group of mAb
with an intermediate level of reactivity that can be
grouped together (Figure 5 panel D mAb-7H5 and panel
F mAb-ZM-38). However, some mAb showed no reactiv-
ity at day seventh (Figure 5 panel A mAb-BG6) compared
with the negative control (Figure 5 panel B-Second Ab).
In addition, variations in the reactivity of the mAb at di-
verse time points were found. Moreover, at day seven it
was found that mAb HP-F1 was negative for Mo-DC and
positive for Mo-LC, thus discriminating Mo-DC from
Mo-LC. Overall, this set of results demonstrates the ex-
istence of antigenic differences between Mo-DC and Mo-
LC, even though there was only a single difference in the
cytokine mixture utilized. Moreover, within the panel
analyzed, it was found that at day 7, there is a mAb that
showed reactivity only against Mo-DC with high FSC
(mAb-TPD153) or against a fraction of Mo-DC (mAb-
DC-LAMP, mAb-55K-2). These results point toward the
existence of subsets within the Mo-DC and Mo-LC popu-
lations.
Of note, the studies on the reactivity of two set of mAb
(mannose receptor and immunoglobulin-like transcript
molecules) raised very interesting considerations about
the role of these antigens in the functionality of DC.
This study showed that DC expressed significant
amounts of two lectin-type receptors: the mannose re-
ceptor (MMR) detected by the mAbs MR 15-2 (CD206),
MMR1.16 (CD206), and MMR190.BB3 (CD206?), and
the antigen DEC-205 detected by the mAbs DEC-205
Table 1: MFI of mAb reactivity against HDC
Day 7 Day 14 Day 21 Day 28
Mo-DC Mo-LC Mo-DC Mo-LC Mo-DC Mo-LC Mo-DC Mo-LC
BG6 72 57 81 149 637 256 644 1100
HP-F1 48 274 160 199 717 310 615 1252
ZM3.8 180 155 332 305 515 226 747 1025
7H5 176 153 366 402 387 221 382 859
42D1 138 129 175 157 278 150 291 562
BU10 50 97 171 172 296 161 392 320
DCGM-4 115 125 177 193 570 288 608 1317
DC-LAMP 148 126 296 205 601 252 567 712
TPD153 124 141 189 198 482 510 657 808
RFD-1 102 113 161 175 374 193 376 712
RFD-7 150 167 209 621 165 114 168 158
CMRF-44 79 111 160 185 348 152 339 115
CMRF-56 193 200 209 203 977 421 974 2232
L25 334 353 279 336 866 890 792 1430
55K-2 237 228 373 215 1029 526 1044 2020
CD1b/c 789 515 392 398 408 234 384 654
DEC-205 162 127 227 171 548 281 430 915
MMR1.16 194 265 319 281 570 272 656 1147
MMR190.BB3 716 570 702 778 881 447 1019 1917
MR15-2 151 278 547 520 721 476 588 817
CMRF-75 155 209 266 234 432 186 403 507
CMRF-82 153 182 340 232 760 357 946 1420
CD1a 801 493 423 603 443 232 354 434
2nd Ab 80 106 121 165 97 81 85 105BMC Immunology (2001) 2:6 http://www.biomedcentral.com/1471-2172/2/6
(CD205) and MMRI-4 (CD205). Both molecules belong
to a family of transmembrane C-type lectins. Both mole-
cules have (i) a cysteine-rich domain, (ii) a fibronectin
type II domain, (iii) multiple C-type carbohydrate recog-
nition-like domains, (iv) a transmembrane domain and
(v) a short cytoplasmic tail [6,12,24,25,27]. Both mole-
cules the MMR [24,25,27] and DEC-205 [6,12], have
been implicated in the uptake of carbohydrate-conjugat-
ed antigens by DC. MMR has been found on the cell sur-
face of macrophages and its carbohydrate recognition
domains mediate the endocytosis of (i) glycoconjugates
containing mannose, (ii) fucose, (iii) acetylglucosamine,
(iv) glucose residues, (v) microorganisms expressing
mannose or acetylglucosamine on the surface. Notably,
all these terminal sugars are neither common membrane
components of mammalian cells nor common compo-
nents of serum proteins. Therefore, it is feasible to con-
sider that this two lectin-type receptors: the mannose
receptor (MMR) and DEC-205 may be involved in the
discrimination between self and non-self antigens as well
and could contribute to enhance the capability of den-
dritic cells to generate primary T cell responses against
infectious agents and soluble antigens that carry these
types of carbohydrates.
In addition, this study provides the first comparison of
the distribution of the MMR and DEC-205 on two hu-
man blood derived DC, Mo-LC and Mo-DC.
A panel of mAb that recognize several immunoglobulin-
like transcript molecules (ILT) was also evaluated in this
study. The mAb HP-F1 (CD85i) identified ILT2 [13],
ZM3.8 (CD85j) recognized ILT3 [17], 42D1 (CD85f)
identified ILT4 [16] and 7H5 (CD85a) recognized ILT5
[15]. One significant feature of the ILTs molecules is
their capability to bind MHC class I molecules [13]. Fur-
thermore, the molecules ILT2, ILT3, ILT4, and ILT5
have been considered to play a role as inhibitory recep-
tors because they carry the immunoreceptor tyrosine-
based inhibitory motif (ITIM) in the intracytoplasmic
tail. Because of (i) the binding capability of ILT2-5 to
MHC class I molecules [13,17], (ii) the presence of inhib-
itory motifs within the cytoplasmic tail of ILT2-5 [13,15–
17] and (iii) the identification of ILT2-5, within diverse
populations of dendritic cells [10,17], is likely that the
ILT molecules identified on DC may not only perform a
key role as the receptor for the "missing self [30] but also
Figure 2
Percentage of positive cells detected by mAb against Mo-DC
and LC-DC after 14 days of culture
Figure 3
Percentage of positive cells detected by mAb against Mo-DC
and LC-DC after 21 days of culture
Figure 4
Percentage of positive cells detected by mAb against Mo-DC
and LC-DC after 28 days of cultureBMC Immunology (2001) 2:6 http://www.biomedcentral.com/1471-2172/2/6
could contribute to control the initial steps of activation
of the immune response; Thus, this would tune up the
fine balance between the activation signals provided by
the simultaneous cross-linking of MHC class I or II and
co-stimulatory molecules during the interaction between
DC with T cells and the inhibitory signals mediated
through the whole variety of ILTs molecules carrying
ITIM motifs. Further functional studies of the role of
ILTs on DC will provide insight toward the understand-
ing of these mechanisms and its role in the regulation of
the DC function.
Conclusions
The immunophenotyping assays described in this report
enabled us to determine in human DC: (i) the existence
of differences between Mo-DC and Mo-LC populations;
(ii) the existence of subsets within the Mo-DC and Mo-
LC populations; (iii) the kinetics of antigens expression
at diverse intervals of time on DC; and (iv) specific mark-
ers for subpopulations of DC.
Material and methods
Monoclonal antibodies (mAb)
A panel of mAb with potential reactivity against DC was
evaluated by setting up a flow cytometry approach. The
panel of antibodies was kindly provided by Dr. D. Hart.
Antibodies are listed in Table 21 {CDIa, CDlb/c, BG6,
HP-F1 (CD85i), BU10, RFD-1, CMRF-44, 7H5 (CD85a),
ZM3.8 (CD85j), 55K-2 (fascin), MMR1.16,
MMR190.BB3 (CD206), L25, CMRF-56, RFD-7, MR15-2
Figure 5
Density plots of Mo-DC and LC-DC reactivity to five mAb after 7 days of culture. Density plot representation of FSC and mAb
reactivity at day seventh has been utilized to demonstrate the presence of significant variability within the Mo-DC and Mo-LC
populations. Panel A displayed mAb-BG6 in comparison with the negative control that is showed in panel B-Second Ab. Panel
C showed mAb-MMR190.BB3. Panel D displayed mAb-7H5. Panel E showed mAb-L25. Panel F displayed mAb-ZM-38.BMC Immunology (2001) 2:6 http://www.biomedcentral.com/1471-2172/2/6
(CD205), DCGM-4 (CD207), TPD153, 42D1 (CD85f),
DEC-205 (CD205), MMRI-4 (CD205), DC-LAMP
(CD208), AZN-D1 (CD209), AZN-D2 (CD209), CMRF-
75, CMRF-82, CD11c, CD80, CD86 and HLA-DR} [12–
29,31]. The panel of antibodies that was utilized in the
Dendritic cell section of the 7th workshop for HLDA is
listed in table 2[12–29].
Cell culture
Adherent PBMC were obtained from a normal healthy
donor and cultured in 25-cm2 tissue culture flasks, with
complete medium for DC culture {Complete Medium:
RPMI 1640 with 25 mM Hepes buffer with L-glutamine
(Gifco BRL, Basel Switzerland), supplemented with 10%
heat-inactivated FBS, and 1 ml of Antibiotic/Antimicotic
(Gifco BRL)} and supplemented with rhGM-CSF (250
ng/ml) +rhIL-4 (100 ng/ml) in order to generate Dermal
DC like (Mo-DC). Adherent PBMC were also cultured in
25-cm2 tissue culture flasks, with rhGM-CSF (250 ng/
ml) +rhIL-4 (100 ng/ml) and rhTGF-pl (10 ng/ml) in or-
der to generate DC like Langerhans cell (Mo-LC) [31]. Af-
terwards, the DC (Mo-DC and Mo-LC) cultures were
incubated at 37°C, 5% CO2 for 7, 14, 21 and 28 days. Eve-
ry week, half volume of the medium was removed and re-
placed with fresh medium without adding additional
cytokines.
The Mo-DC and Mo-LC populations were harvested and
evaluated at 7, 14, 21 and 28 days
Flow cytometry analysis
Cells (105 cells/l00 ul) were incubated with 10 µl of mAb
on ice for 30'. Cells were washed, twice with wash buffer
(Becton Dickinson, San Jose Ca), and stained with 10 µl
(1:100 antibody dilution) anti-mouse Ig FITC-labeled on
ice for 30', washed once and fixed with Cellfix™ (Becton
Dickinson, San Jose Ca). Thereafter, cells were acquired
(104 cells per sample) and analyzed on a FACSCalibur
(Becton Dickinson, San Jose Ca). Cells were acquired
and gated by FSC and SSC. The gated cells were analyzed
by (i) histograms displaying the fluorescent reactivity
collected in fluorescence 1 (green channel); (ii) Density
plots displaying the fluorescent reactivity collected in
fluorescence 1 (green channel) against the FSC [31]. Flow
Table 2: List of monoclonal antibodies
Sample Panel number Monoclonal antibody (CD*) Reference
1 70011 BG6 12
2 70194 HP-Fl(CD85i)ILT2 13
3 70293 BU10 14
4 70345 7H5 (CD85a) ILT5 15
5 70346 42D1 (CD85f)ILT4 16
6 70358 ZM3.8 (CD85j) ILT3 17
7 70427 DCGM-4 (CD207) Langerin 18
8 70435 DC-LAMP (CD208) 19
9 70451 TPD153 20
10 70511 RFD-1 21
11 70512 RFD-7 22
12 70375 CMRF-44 7
13 70376 CMRF-56 23
14 70802 MR15-2 (CD206) 24
15 70808 DEC-205 (CD205) 6,12,25
16 70807 CDlb/c 31
17 70806 55K-2 fascin 26
18 70776 MMR1.16 (CD206) 27
19 70767 MMR190.BB3 (CD206?) 27
20 70772 L25 28
21 Positive Control 1 CMRF-75 12
22 Positive Control 2 CMRF-82 12
23 Positive Control 3 CD1a 31
24 Second Ab 2nd Ab 31
25 70875 AZN-D1 (CD209) 29
26 70876 AZN-D2 (CD209) 29
27 70874 MMRI-4 (CD205) 12,25
(CD*): Hart DNJ., Clark GJ. MacDonald K., Kato M., Vuckovic S., Lopez A., Wykes M., Munster D.. 7th Leucocyte Differentiation antigen workshop, 
DC section summary. D. Mason, Editor, Leukocyte Typing VII, Oxford University Press. Oxford. In Press 2001 [12]BMC Immunology (2001) 2:6 http://www.biomedcentral.com/1471-2172/2/6
cytometry measurement on non-stained or stained only
with the second antibody (secondary antibody) were per-
formed and used as control populations. Secondary anti-
body only stained cells at day 7 served to determine the
markers and the quadrant borders. At least 99% of these
cells were located in the lower left quadrant (negative).
Three independent experiments were performed. Data
were analyzed with CellQuest (Becton Dickinson, San
Jose Ca). Statistical analysis (mean, standard deviation
and graphics) was performed with Microsoft Excel.
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